The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 06, 2026

Filed:

Mar. 16, 2022
Applicant:

Tolmar International Limited, Dublin, IE;

Inventors:

Avinash Nangia, Fort Collins, CO (US);

John Arthur Mclane, Loveland, CO (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/09 (2006.01); A61K 9/00 (2006.01); A61K 47/22 (2006.01); A61K 47/34 (2017.01); A61M 5/19 (2006.01); A61P 15/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/09 (2013.01); A61K 9/0019 (2013.01); A61K 47/22 (2013.01); A61K 47/34 (2013.01); A61M 5/19 (2013.01); A61P 15/00 (2018.01);
Abstract

An extended release formulation is provided for use in a method for the treatment of Central Precocious Puberty (CPP) in pediatric patients 2 years of age or older. The extended release formulation comprises leuprolide or a pharmaceutically acceptable salt thereof, a biodegradable polymer, and a biocompatible organic solvent. The biodegradable polymer is comprised of poly(lactide-co-glycolide) (PLG) copolymer segments, poly(lactic acid-co-glycolic acid) (PLGA) copolymer segments, poly(lactide) (PL) polymer segments, poly(lactic acid) (PLA) polymer segments, or a combination thereof. The extended release formulation is administered as a subcutaneous injection of a flowable composition that forms a solid in situ depot. The extended release formulation releases leuprolide for a period of about 6 months for the effective treatment of CPP within a pediatric patient.


Find Patent Forward Citations

Loading…